AIM ImmunoTech 宣布在《美国癌症研究杂志》上发表一项评估 Ampligen® 治疗胰腺癌的临床前研究取得的积极结果。
佛罗里达州奥卡拉, June 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”或“公司”）今日宣布发表临床前数据，数据表明 Ampligen 有可能直接作用于肿瘤细胞，抑制肿瘤细胞在肿瘤 TLR-3…
Browsing Tag
NYSE:AIM
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study…
OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its…
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic…
<!-- Name:DistributionId Value:8777896 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the…
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the…
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in…
OCALA, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of…
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
OCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of…
AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium…
OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of…
AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an…
Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4,…
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment…
Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients…
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate…
– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve…